title: Histomorphometric characteristics of immune cells in small intestine of pigs perorally immunized with vaccine candidate F18ac nonenterotoxigenic E. coli strain.
abstract: Colidiarrhea and colienterotoxemia caused by F4(+) and/or F18(+) enterotoxigenic E. coli (ETEC) strains are the most prevalent infections of suckling and weaned pigs. Here we tested the immunogenicity and protective effectiveness of attenuated F18ac(+) non-ETEC vaccine candidate strain against challenge infection with F4ac(+) ETEC strain by quantitative phenotypic analysis of small intestinal leukocyte subsets in weaned pigs.We also evaluated levamisole as an immune response modifier (IRM) and its adjuvanticity when given in the combination with the experimental vaccine. The pigs were parenterally immunized with either levamisole (at days -2, -1 and 0) or with levamisole and perorally given F18ac(+) non-ETEC strain (at day 0), and challenged with F4ac(+) ETEC strain 7 days later.At day 13 the pigs were euthanatized and sampled for immunohistological/histomorphometrical analyses. Lymphoid CD3(+), CD45RA(+), CD45RC(+), CD21(+), IgA(+) and myeloid SWC3(+) cell subsets were identified in jejunal and ileal epithelium, lamina propria and Peyer's patches using the avidin-biotin complex method, and their numbers were determined by computer-assisted histomorphometry. Quantitative immunophenotypic analyses showed that levamisole treated pigs had highly increased numbers of jejunal CD3(+), CD45RC(+) and SWC3(+) cells (p<0.05) as compared to those recorded in nontreated control pigs.In the ileum of these pigs we have recorded that only CD21(+) cells were significantly increased (p<0.01). The pigs that were treated with levamisole adjuvanted experimental vaccine had significantly increased numbers of all tested cell subsets in both segments of the small intestine. It was concluded that levamisole adjuvanted F18ac(+) non-ETEC vaccine was a requirement for the elicitation of protective gut immunity in this model; nonspecific immunization with levamisole was less effective, but confirmed its potential as an IRM.
authors.affiliation: Department of Biology, University of Zagreb, Croatia.
authors.forename: A
authors.initials: A
authors.lastname: Kovšca Janjatović
authors.forename: G
authors.initials: G
authors.lastname: Lacković
authors.forename: F
authors.initials: F
authors.lastname: Božić
authors.forename: D
authors.initials: D
authors.lastname: Spoljarić
authors.forename: M
authors.initials: M
authors.lastname: Popović
authors.forename: H
authors.initials: H
authors.lastname: Valpotić
authors.forename: N
authors.initials: N
authors.lastname: Vijtiuk
authors.forename: Z
authors.initials: Z
authors.lastname: Pavičić
authors.forename: I
authors.initials: I
authors.lastname: Valpotić
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D054307:Enterotoxigenic Escherichia coli / Q000276:immunology / Q000472:pathogenicity; D004926:Escherichia coli / Q000276:immunology; D004927:Escherichia coli Infections / Q000276:immunology* / Q000662:veterinary*; D022361:Escherichia coli Vaccines / Q000008:administration & dosage* / Q000276:immunology; D007111:Immunity, Cellular; D018928:Immunity, Mucosal / Q000276:immunology; D007413:Intestinal Mucosa / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D007421:Intestine, Small / Q000276:immunology* / Q000378:metabolism; D007978:Levamisole / Q000008:administration & dosage* / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D013552:Swine; D013553:Swine Diseases / Q000276:immunology / Q000517:prevention & control*
chemical_list: D000276:Adjuvants, Immunologic; D022361:Escherichia coli Vaccines; D007978:Levamisole
references.citation: Br Vet J. 1989 Nov-Dec;145(6):565-72
references.pmid: 2590827
references.citation: Int J Med Microbiol. 2005 Oct;295(6-7):443-54
references.pmid: 16238018
references.citation: FEMS Microbiol Lett. 2005 Mar 15;244(2):281-9
references.pmid: 15766780
references.citation: Vet Res. 1999 Mar-Jun;30(2-3):259-84
references.pmid: 10367358
references.citation: Infect Immun. 1992 Apr;60(4):1285-94
references.pmid: 1347758
references.citation: Vaccine. 2006 May 1;24(18):3812-20
references.pmid: 16099554
references.citation: Vet Microbiol. 2007 Jul 20;123(1-3):145-52
references.pmid: 17368762
references.citation: Vet Microbiol. 2005 Sep 30;110(1-2):35-9
references.pmid: 16026940
references.citation: Vet Microbiol. 2000 Feb;71(3-4):255-67
references.pmid: 10703708
references.citation: Vaccine. 1992;10(2):75-88
references.pmid: 1539467
references.citation: Vet Immunol Immunopathol. 1994 Oct;43(1-3):143-50
references.pmid: 7856046
references.citation: J Vet Pharmacol Ther. 2003 Jun;26(3):225-31
references.pmid: 12755907
references.citation: Infect Immun. 1992 Feb;60(2):485-90
references.pmid: 1730480
references.citation: Anim Health Res Rev. 2005 Jun;6(1):17-39
references.pmid: 16164007
references.citation: J Vet Pharmacol Ther. 2002 Feb;25(1):69-72
references.pmid: 11874530
references.citation: Nature. 1966 Mar 12;209(5028):1084-6
references.pmid: 5925183
references.citation: Vet Microbiol. 1990 Nov;25(2-3):267-81
references.pmid: 1980757
references.citation: J Vet Pharmacol Ther. 1986 Jun;9(2):119-39
references.pmid: 2425099